DocumentsDate added
Review article:-Periodontology & oral implantology
Sweta Kumari Singh1* , Vidya Dodwad2 & Garima Dhariwal3
1Post graduate Student, 2Professor and HOD, 3Post graduate Student, Department of Periodontology & oral implantology, I.T.S. Centre for Dental Studies and Research, Delhi-Meerut Road, Murad Nagar, Ghaziabad- 201206, India.
Abstract:- Periodontitis is an “infectious disease resulting in inflammation within the supporting tissues of the teeth, progressive attachment loss and bone loss”. Periodontal therapy is aimed at the restoration of tissues destroyed by disease. However, achieving greater predictability with regenerative therapy requires the introduction of an agent which not only hampers tissue destruction but also enhances the regenerative capabilities of the periodontal tissues. Simvastatin is a hypolipidemic drug used to control elevated cholesterol, or hypercholesterolemia. It is a member of the statin class of pharmaceuticals. The primary uses of simvastatin are for the treatment of dyslipidemia and the prevention of cardiovascular disease. Simvastatin has been reported to promote osteoblastic activity and inhibit osteoclastic activity by inhibiting a rate-limiting enzyme of the cholesterol synthesis pathway. Locally applied simvastatin induces osteogenesis and bone growth by upregulation of BMP-Various animal and human studies showed that SMV assists in bone regeneration and has an anti-inflammatory effect when delivered or applied locally.
Key words:- Simvastatin, periodontal therapy, bone regeneration, BMP-2.